m6A甲基化修饰在肿瘤免疫中的作用及干预策略

doi:10.3969/j.issn.1000-8535.2023.02.001

广州医药 ›› 2023, Vol. 54 ›› Issue (2): 1-8.DOI: 10.3969/j.issn.1000-8535.2023.02.001

• 专家综述 • 下一篇

m⁶A甲基化修饰在肿瘤免疫中的作用及干预策略

彭彦茜¹, 易诚², 陶丽君², 王红胜²

1 湘南学院基础医学院(郴州 423000)
2 中山大学药学院(广州 510006)

收稿日期:2022-12-12 出版日期:2023-02-20 发布日期:2023-02-27
通讯作者: 王红胜,中山大学药学院教授、博导、副院长、教育部青年长江学者。目前主要研究RNA修饰在肿瘤中的作用及其靶向治疗策略。先后主持国家重点研发计划青年项目、广东省自然基金卓越青年团队项目、6项国家自然基金(国际合作1项、面上4项、青年1项)、广东省自然科学基金杰出青年基金等10多项课题。获中国药理学会施维雅青年药理学家奖(2019)、中国药学会以岭生物医药奖青年奖(2019)、中国药理学会青年药理学家奖(2018)、中国药学会赛诺菲青年生物药物奖(2016)。近五年以通讯及第一作者在Proceedings of the National Academy of Sciences of the United States of America、Nature Communications等SCI期刊发表论文60余篇。总计引用次数超过5 500次,h-index 为45,入选全球顶尖前10万科学家,全球前2%顶尖科学家榜单。E-mail: whongsh@mail.sysu.edu.cn
基金资助:
国家重点研发计划青年项目(2022YFC2601800); 国家自然基金项目(32161143017,82173833,81973343)

The roles of m⁶A methylation in tumor immunity and targeted therapy strategies

PENG Yanxi¹, YI Cheng², TAO Lijun², WANG Hongsheng²

1 School of Basic Medical Sciences, Xiangnan University, Chenzhou 423000, China
2 School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China

Received:2022-12-12 Online:2023-02-20 Published:2023-02-27

摘要/Abstract

摘要： N⁶-甲基腺苷(N⁶-methyladenosine, m⁶A)修饰是真核生物信使 RNA中最丰富的表观遗传修饰,其失调会导致mRNA异常生物学行为如翻译和降解紊乱,从而调控肿瘤发生发展。近期研究表明m⁶A在免疫调控过程中可发挥重要作用,其不仅可调节免疫细胞的活化,还在肿瘤微环境中免疫应答发挥重要调控作用,从而影响免疫治疗效果。越来越多的证据表明m⁶A修饰可能是肿瘤免疫治疗的重要潜在干预靶点。本文阐述了免疫细胞中m⁶A修饰调控及其在肿瘤免疫微环境中相关调节作用,并进一步探讨了靶向m⁶A调控蛋白在肿瘤免疫治疗中的干预策略及潜在治疗价值。

关键词: m⁶A甲基化, 肿瘤免疫, 肿瘤微环境, 靶向治疗

Abstract: N⁶-methyladenosine (m⁶A) modification is the most abundant epigenetic modification in eukaryotic messenger RNA (messenger RNA). Its dysregulation drives abnormal transcription and translation processes, which promotes the occurrence and development of tumors. Studies have shown that m⁶A modification can regulate the activation of immune cells and their infiltration into the tumor microenvironment (TME), which may affect the efficiency of immunotherapy. Therefore, m⁶A modification may be a potential target for tumor immunotherapy. This paper describes the modification of m⁶A in immune cells and the antitumor immune response associated with TME, and explores the potential therapeutic value of targeting m⁶A regulators in tumor immunotherapy.

Key words: m⁶A methylation, tumor immunity, tumor microenvironment, targeted therapy

彭彦茜, 易诚, 陶丽君, 王红胜. m⁶A甲基化修饰在肿瘤免疫中的作用及干预策略[J]. 广州医药, 2023, 54(2): 1-8.

PENG Yanxi, YI Cheng, TAO Lijun, WANG Hongsheng. The roles of m⁶A methylation in tumor immunity and targeted therapy strategies[J]. Guangzhou Medical Journal, 2023, 54(2): 1-8.

参考文献

[1] ROUNDTREE I A,EVANS M E,PAN T,et al. Dynamic RNA modifications in gene expression regulation[J]. Cell,2017,169(7):1187-1200.
[2] ZHAO B S,ROUNDTREE I A,HE C.Post-transcriptional gene regulation by mRNA modifications[J]. Nat Rev Mol Cell Biol, 2017,18(1):31-42.
[3] FU Y,DOMINISSINI D,RECHAVI G,et al. Gene expression regulation mediated through reversible m⁶A RNA methylation[J]. Nat Rev Genet,2014,15(5):293-306.
[4] LIU J,YUE Y, HAN D, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N⁶-adenosine methylation[J]. Nat Chem Biol, 2014,10(2):93-95.
[5] JIA G, FU Y, ZHAO X, et al. N⁶-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO[J]. Nat Chem Biol,2011,7(12):885-887.
[6] ZHENG G,DAHL J A,NIU Y,et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility[J]. Mol Cell,2013,49(1):18-29.
[7] WANG X,LU Z,GOMEZ A,et al. N⁶-methyladenosine-dependent regulation of messenger RNA stability[J]. Nature, 2014,505(7481):117-120.
[8] WANG X,ZHAO B S,ROUNDTREE I A,et al. N⁶-methyladenosine Modulates Messenger RNA Translation Efficiency[J]. Cell,2015,161(6):1388-1399.
[9] TAKABA H, TAKAYANAGI H.The mechanisms of T cell selection in the thymus[J]. Trends Immunol,2017,38(11):805-816.
[10] LI H B,TONG J,ZHU S,et al. m⁶A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways[J]. Nature,2017,548(7667):338-342.
[11] CROTTY S.T Follicular helper cell biology: A decade of discovery and diseases[J]. Immunity,2019,50(5):1132-1148.
[12] YAO Y,YANG Y,GUO W,et al. METTL3-dependent m⁶A modification programs T follicular helper cell differentiation[J]. Nat Commun,2021,12(1):1333.
[13] TONG J,CAO G,ZHANG T,et al. m⁶A mRNA methylation sustains Treg suppressive functions[J]. Cell Res,2018,28(2):253-256.
[14] LIU Z,WANG T,SHE Y,et al. N⁶-methyladenosine-modified circIGF2BP3 inhibits CD8⁺ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer[J]. Mol Cancer,2021,20(1):105.
[15] DONG L,CHEN C,ZHANG Y,et al. The loss of RNA N⁶-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8⁺ T cell dysfunction and tumor growth[J]. Cancer Cell,2021,39(7):945-957.
[16] LU T X, ZHENG Z, ZHANG L, et al. A new model of spontaneous colitis in mice induced by deletion of an RNA m⁶A methyltransferase component METTL14 in T cells[J]. Cell Mol Gastroenterol Hepatol,2020,10(4):747-761.
[17] ZHOU J,ZHANG X,HU J,et al. m⁶A demethylase ALKBH5 controls CD4⁺ T cell pathogenicity and promotes autoimmunity[J]. Sci Adv,2021,7(25):eabg0470.
[18] DING C, XU H, YU Z, et al. RNA m⁶A demethylase ALKBH5 regulates the development of γδ T cells[J]. Proc Natl Acad Sci U S A, 2022,119(33):e2203318119.
[19] HUANG H,ZHANG G,RUAN G X,et al. Mettl14-Mediated m⁶A modification is essential for germinal center B cell response[J]. J Immunol, 2022,208(8):1924-1936.
[20] ZHENG Z, ZHANG L, CUI X L, et al. Control of early B cell development by the RNA N⁶-Methyladenosine methylation[J]. Cell Rep,2020,31(13):107819.
[21] KANG X, CHEN S, PAN L, et al. Deletion of mettl3 at the pro-B stage marginally affects B cell development and profibrogenic activity of B cells in liver fibrosis[J]. J Immunol Res,2022(2022):8118577.
[22] NOY R,POLLARD J W.Tumor-associated macrophages: from mechanisms to therapy[J]. Immunity,2014,41(1):49-61.
[23] TONG J,WANG X,LIU Y,et al. Pooled CRISPR screening identifies m⁶A as a positive regulator of macrophage activation[J]. Sci Adv,2021,7(18):eabd4742.
[24] WANG X,JI Y,FENG P,et al. The m⁶A reader IGF2BP2 regulates macrophage phenotypic activation and inflammatory diseases by stabilizing TSC1 and PPARγ[J]. Adv Sci (Weinh),2021,8(13):2100209.
[25] GUO M,YAN R,JI Q,et al. IFN regulatory Factor-1 induced macrophage pyroptosis by modulating m⁶A modification of circ_0029589 in patients with acute coronary syndrome[J]. Int Immunopharmacol,2020(86):106800.
[26] SUN Z, CHEN W, WANG Z, et al. Matr3 reshapes m⁶A modification complex to alleviate macrophage inflammation during atherosclerosis[J]. Clin Immunol,2022(245):109176.
[27] ZHOU K, CHENG T, ZHAN J, et al. Targeting tumor-associated macrophages in the tumor microenvironment[J]. Oncol Lett,2020,20(5):234.
[28] LIU Y,LIU Z,TANG H,et al. The N⁶-methyladenosine (m⁶A)-forming enzyme METTL3 facilitates M1 macrophage polarization through the methylation of STAT1 mRNA[J]. Am J Physiol Cell Physiol, 2019,317(4):C762-C775.
[29] YIN H,ZHANG X,YANG P,et al. RNA m⁶A methylation orchestrates cancer growth and metastasis via macrophage reprogramming[J]. Nat Commun,2021,12(1):1394.
[30] SHI B,LIU W W,YANG K,et al. The role, mechanism, and application of RNA methyltransferase METTL14 in gastrointestinal cancer[J]. Mol Cancer,2022,21(1):163.
[31] LIU Y,SHI M,HE X,et al. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m⁶A-reader IGF2BP2 in pancreatic ductal adenocarcinoma[J]. J Hematol Oncol, 2022,15(1):52.
[32] MORVAN M G, LANIER L L.NK cells and cancer: you can teach innate cells new tricks[J]. Nat Rev Cancer,2016,16(1):7-19.
[33] SPITS H, BERNINK J H, LANIER L. NK cells and type 1 innate lymphoid cells: partners in host defense[J]. Nat Immunol,2016,17(7):758-764.
[34] MA S,YAN J,BARR T, et al. The RNA m⁶A reader YTHDF2 controls NK cell antitumor and antiviral immunity[J]. J Exp Med,2021,218(8):e20210279.
[35] SONG H,SONG J,CHENG M,et al. METTL3-mediated m⁶A RNA methylation promotes the anti-tumour immunity of natural killer cells[J]. Nat Commun,2021,12(1):5522.
[36] STEINMAN R M,BANCHEREAU J.Taking dendritic cells into medicine[J]. Nature,2007,449(7161):419-426.
[37] WANG H,HU X,HUANG M,et al. Mettl3-mediated mRNA m⁶A methylation promotes dendritic cell activation[J]. Nat Commun,2019,10(1):1898.
[38] WU H, XU Z, WANG Z,et al. Dendritic cells with METTL3 gene knockdown exhibit immature properties and prolong allograft survival[J]. Genes Immun,2020,21(3):193-202.
[39] HAN D,LIU J,CHEN C,et al. Anti-tumour immunity controlled through mRNA m⁶A methylation and YTHDF1 in dendritic cells[J]. Nature,2019,566(7743):270-274.
[40] BINNEWIES M, ROBERTS E W, KERSTEN K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy[J]. Nat Med,2018,24(5):541-550.
[41] TANG H,QIAO J,FU Y X.Immunotherapy and tumor microenvironment[J]. Cancer Lett, 2016, 370(1):85-90.
[42] LU M, ZHANG Z, XUE M, et al. N⁶-methyladenosine modification enables viral RNA to escape recognition by RNA sensor RIG-I[J]. Nat Microbiol,2020,5(4):584-598.
[43] SHULMAN Z,STERN-GINOSSAR N.The RNA modification N⁶-methyladenosine as a novel regulator of the immune system[J]. Nat Immunol,2020,21(5):501-512.
[44] TSIAMBAS E,CHRYSOVERGIS A,PAPANIKOLAOU V, et al. Impact of Ribosome Activity on SARS-CoV-2 LNP-Based mRNA Vaccines[J]. Front Mol Biosci,2021(8):654866.
[45] LAN H,LIU Y,LIU J,et al. Tumor-associated macrophages promote oxaliplatin resistance via METTL3-mediated m⁶A of TRAF5 and necroptosis in colorectal cancer[J]. Mol Pharm,2021,18(3):1026-1037.
[46] SHEN S, YAN J, ZHANG Y,et al. N⁶-methyladenosine (m⁶A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma[J]. Ann Transl Med,2021,9(1):59.
[47] LUO Y,SUN Y,LI L,et al. METTL3 may regulate testicular germ cell tumors through EMT and immune pathways[J]. Cell Transplant, 2020(29):963689720946653.
[48] WANG L, HUI H, AGRAWAL K,et al. m⁶ A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy[J]. EMBO J,2020,39(20):e104514.
[49] NI H H,ZHANG L,HUANG H,et al. Connecting METTL3 and intratumoural CD33⁺ MDSCs in predicting clinical outcome in cervical cancer[J]. J Transl Med,2020,18(1):393.
[50] HE X, TAN L, NI J, et al. Expression pattern of m⁶A regulators is significantly correlated with malignancy and antitumor immune response of breast cancer[J]. Cancer Gene Ther,2021,28(3-4):188-196.
[51] YI L,WU G,GUO L,et al. Comprehensive analysis of the PD-L1 and immune infiltrates of m⁶A RNA methylation regulators in head and neck squamous cell carcinoma[J]. Mol Ther Nucleic Acids, 2020(21):299-314.
[52] GONG P J,SHAO Y C,YANG Y,et al. Analysis of N⁶-Methyladenosine methyltransferase reveals METTL14 and ZC3H13 as tumor suppressor genes in breast cancer[J]. Front Oncol,2020(10):578963.
[53] LIU Y,LIANG G,XU H,et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance[J]. Cell Metab,2021,33(6):1221-1233.e11.
[54] YANKOVA E,BLACKABY W,ALBERTELLA M,et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia[J]. Nature,2021,593(7860):597-601.
[55] CHEN B,YE F,YU L,et al. Development of cell-active N⁶-methyladenosine RNA demethylase FTO inhibitor[J]. J Am Chem Soc,2012,134(43):17963-17971.
[56] HUANG Y, YAN J, LI Q, et al. Meclofenamic acid selectively inhibits FTO demethylation of m⁶A over ALKBH5[J]. Nucleic Acids Res,2015,43(1):373-384.
[57] WANG R, HAN Z, LIU B, et al. Identification of natural compound radicicol as a potent FTO inhibitor[J]. Mol Pharm,2018,15(9):4092-4098.
[58] HE W, ZHOU B, LIU W, et al. Identification of a novel small-molecule binding site of the fat mass and obesity associated protein (FTO)[J]. J Med Chem,2015,58(18):7341-7348.
[59] PENG S, XIAO W, JU D, et al. Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1[J]. Sci Transl Med,2019,11(488):eaau7116.
[60] SU R,DONG L,LI C,et al. R-2HG exhibits anti-tumor activity by targeting FTO/m⁶A/MYC/CEBPA signaling[J]. Cell,2018,172(1-2):90-105.e23.
[61] HUANG Y,SU R,SHENG Y,et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia[J]. Cancer Cell,2019,35(4):677-691.e10.
[62] SU R, DONG L, LI Y, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion[J]. Cancer Cell,2020,38(1):79-96.e11.
[63] HAN X,WANG N,LI J,et al. Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity[J]. Chem Biol Interact,2019(297):80-84.
[64] XIE L J,YANG X T,WANG R L, et al. Identification of flavin mononucleotide as a cell-Active artificial N⁶ -methyladenosine RNA demethylase[J]. Angew Chem Int Ed Engl,2019,58(15):5028-5032.
[65] KZHYSHKOWSKA J,LARIONOVA I,LIU T.YKL-39 as a potential new target for anti-Angiogenic therapy in cancer[J]. Front Immunol, 2020(10):2930.
[66] WANG W,MARINIS J M,BEAL A M,et al. RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer[J]. Cancer Cell,2018,34(5):757-774.e7.

m⁶A甲基化修饰在肿瘤免疫中的作用及干预策略

The roles of m⁶A methylation in tumor immunity and targeted therapy strategies

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价